Paradigm Biopharmaceuticals

What is Paradigm Biopharmaceuticals about?
Paradigm Biopharmaceuticals (ASX:PAR) is an Australian biotechnology company developing injectable pentosan polysulfate sodium (iPPS) for the treatment of osteoarthritis (OA). OA is a degenerative joint disease that affects millions of people worldwide, and there is currently no cure. Paradigm's operations are focused on the development and commercialisation of iPPS. The company is currently conducting Phase 3 clinical trials of iPPS for the treatment of knee OA, and it expects to submit regulatory applications for approval in 2024. Paradigm is also exploring the use of iPPS to treat other forms of OA, such as hip and shoulder OA.
Paradigm Biopharmaceuticals company media
Company Snapshot

Is Paradigm Biopharmaceuticals a public or private company?


How many people does Paradigm Biopharmaceuticals employ?


What sector is Paradigm Biopharmaceuticals in?

Health Care

Where is the head office for Paradigm Biopharmaceuticals?

Head Office
Victoria, Australia

What year was Paradigm Biopharmaceuticals founded?

Year Founded
What does Paradigm Biopharmaceuticals specialise in?
/Biotech /Pharmaceutical /Health /Medtech /Technology /Drug /Medical
Icon representing a globe with map pin
Where does Paradigm Biopharmaceuticals operate? Locations of Paradigm Biopharmaceuticals global operations


  • Map pin icon
    Global view
  • Map pin icon
    Melbourne, Australia
Global operations world map
What are Paradigm Biopharmaceuticals’s services?
Overview of Paradigm Biopharmaceuticals offerings
Osteoarthritis: Paradigm Biopharmaceuticals is developing Zilosul® (iPPS) for the treatment of osteoarthritis, with Phase 3 trials underway.
Respiratory: Paradigm Biopharmaceuticals is developing Pentosan Polysulfate Sodium to target ARDS based on its multiple mechanisms of action outlined in preclinical studies.
Lysosomal Storage Diseases: Paradigm Biopharmaceuticals is developing Pentosan Polysulfate Sodium to help manage bone and joint manifestations, chronic pain, and physical disability, key clinical manifestations of MPS I which remain despite treatment with HSCT and ERT.
Who is in the Paradigm Biopharmaceuticals executive team?
Paradigm Biopharmaceuticals leadership team
  • Mr. Paul John Rennie BSc, Grad Dip, MBM, MSTC
    Mr. Paul John Rennie BSc, Grad Dip, MBM, MSTC
    Founder, MD & Exec. Chairman
  • Dr. Donna L. Skerrett M.D., MS
    Dr. Donna L. Skerrett M.D., MS
    Chief Medical Officer and Exec. Director
  • Mr. Justin  Cahill
    Mr. Justin Cahill
    Chief Financial Officer
  • Dr. Ravi  Krishnan
    Dr. Ravi Krishnan
    Chief Scientific Officer
  • Mr. Simon  White
    Mr. Simon White
    Director of Investor Relations
  • Dr. Michael  Imperiale
    Dr. Michael Imperiale
    Global Head of Drug Safety & MPS
  • Ms. Beverley  Huttmann
    Ms. Beverley Huttmann
    Commercial Head
  • Ms. Michelle  Coffey
    Ms. Michelle Coffey
    Global Head of Regulatory Affairs